<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Isochromosome 17q is a relatively common karyotypic abnormality in <z:hpo ids='HP_0002885'>medulloblastoma</z:hpo>, gastric, bladder, and <z:hpo ids='HP_0003002'>breast cancers</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In myeloid disorders, it is observed during disease progression and evolution to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in Philadelphia-positive <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>It has been reported in rare cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, with an incidence of 0.4-1.57% </plain></SENT>
<SENT sid="3" pm="."><plain>Two new agents have been approved for treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These are the hypomethylating agents, <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi>, recommended by consensus guidelines for high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients not eligible for hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>We present a case of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> with <z:mpath ids='MPATH_458'>normal</z:mpath> cytogenetics at diagnosis treated with <z:chebi fb="0" ids="50131">decitabine</z:chebi> (with good response); however, the patient evolved to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with i(17q) shortly after suspending treatment </plain></SENT>
<SENT sid="6" pm="."><plain>To the best of our knowledge, this is the first report of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes with i(17q) after the use of a hypomethylating agent </plain></SENT>
</text></document>